Credit Suisse Says Downside in Accretive Health (AH) Shares 'Overdone'

Shares of Accretive Health (NYSE: AH) are bouncing modestly Thursday afternoon following a jaw-dropping 42 percent decline on Wednesday amid concerns of a Minnesota Attorney General suit against the company. The stock last traded at $11.45, up 6.6 percent for the session.

Certainly helping push the stock higher Thursday, Credit Suisse's Glen Santangelo issued a research note this morning suggesting the recent sell-off is overdone. While the analyst said the compliance review may force Accretive Health to alter some business practices, Santangelo believes any "egregious legal violations."

Credit Suisse maintains an Outperform rating and $32 price target on shares of Accretive Health.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Cummins (CMI) PT Lowered to $675 at Jefferies
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'